Pharma & Biotech Global Week in Review 22 July 09 from IP Think Tank

Here is IP Think Tank’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page:

Highlights this week included:

India: Tarceva patent to be reviewed by Indian Supreme Court: Roche v Cipla (Spicy IP) (GenericsWeb)

US follow-on biologics data exclusivity debate (Patent Docs) (Patent Docs) (IP Watchdog) (Managing Intellectual Property) (Patently BIOtech) (Patent Docs) (Patent Docs)


Shift in IP top posts at WHO (Intellectual Property Watch)

ECOSOC calls for intensified efforts on public health and use of TRIPS flexibilities (Intellectual Property Watch)

Canada: Federal Court upholds data exclusivity rules for pharmaceutical manufacturers: Canadian Generic Pharmaceutical Association v Minister of Health / Apotex v Minister of Health (Pharmacapsules @ Gowlings)

EU: European Commission’s competition inquiry into the pharmaceutical sector (Spicy IP) (GenericsWeb)

EU: Date fixed for ECJ ruling on references relating to SPCs in Manufacturing BV v Bureau voor de Industriële Eigendom, also operating under the name Octrooicentrum Nederland (The SPC Blog)

India: USIBC report on incremental innovation: an analysis (Spicy IP)

India: Incremental patents: IPAB creates confusion (Part 1 – Patent Circle), (Part II – Patent Circle) (Part III – Patent Circle)

Israel: Pharma Israel backs appeal of drug patent case: H Lundbeck v Manufacturers Association of Israel and Unipharm (GenericsWeb)

UK Parliament report: Health access a ‘treatment timebomb’ (Intellectual Property Watch)

US: ITC judge denies joint motion to terminate investigation in non-shellfish derived glucosamine (ITC 337 Law Blog)

US: CAFC mows down bean patent – reading between the rows: In re Pod-Ners (Patents4Life)

US: House Subcommittee on the Courts and Competition Policy hearing on follow-on biologics ‘Biologics and Biosimilars: Balancing Incentives for Innovation’ (Patent Docs) (Patent Docs)

US: Howard Dean supports strong protection for biologics (IP Watchdog)

US: Blow to biosimilars in amended US health care act (Managing Intellectual Property)

US: BIO CEO: Patient groups join call for data protection (Patently BIOtech)

US: Follow-on biologics news brief – no 5 (Patent Docs)

US: The risk of biogenerics (Patent Docs)

US: DoJ switches position and narrows the playing field for reverse payments in Hatch-Waxman settlements (FDA Law Blog)

Venezuela: Ironically, it seems Big Pharma is preferred by Venezuelan people (Patent Docs)


Air-tel, Biofenac (Aceclofenac) – Belgium: Brussels Court of Appeal decides on calculation of duration of SPC: Almirall v Mylan (The SPC Blog)

Delsym (Dextromethorphan) – US: Tris Pharma files ANDA with Para IV certification for generic equivalent to Reckitt Benckiser’s Delsym (GenericsWeb)

Eloxatin (Oxaliplatin) – US: Sanofi-Aventis, Ebewe Pharma settle Eloxatin patent litigation (Patent Docs)

Ferrochel – US: Albion and Lannett resolve patent suit over Ferrochel (Patent Docs)

Glivec (Imatinib) – India: Novartis challenges IPAB’s Glivec decision – taking the issue to the WTO? (PatLit)

Levaquin (Levofloxacin) – US: CAFC awards only partial costs where depositions used in multiple cases from different district courts: Ortho-McNeil Pharmaceutical, Inc. v. Mylan Inc (Global IP Watch)

Lexapro (Escitalopram) – US: Forest and Sun settle Lexapro patent suit (Patent Docs)

Lovenox (Enoxaparin) – US: Judge denies attorney fees to Sandoz in patent infringement dispute with Sanofi-Aventis (Patent Docs)

Norflox-TZ (Norfloxacin) and Aerocort (Salbutamol) – India: Cipla attracts NPPA’s attention again – alleged overpricing of Salbutamol and Norfloxacin (Spicy IP)

Ovide (Malathion) – US: Taro receives US patent for Ovide (SmartBrief)

OxyContin (Oxycodone) – US: Purdue loses bid for dismissal of Alphapharm’s lawsuit relating to Oxycontin (Patent Docs)

Sanctura (Trospium) – US: Watson confirms filing of ANDA for generic Sanctura prior to expiration of Supernus’ patent (GenericsWeb)

Strovite Advance , Vitafol OB – US: Settlement announced in Everett dispute with Breckenridge over Vitafol and Strovite Advance patents (Patent Docs)

Tarceva (Erlotinib) – India: Tarceva patent to be reviewed by Indian Supreme Court: Roche v Cipla (Spicy IP) (GenericsWeb)


%d bloggers like this: